SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system,
C&F Financial (NASDAQ:CFFI) reported quarterly earnings of $1.85 per share. This is a 13.15 percent decrease over earnings of $2.13 per share from the same period last year.